Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in SCCHN
NCT00281866Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2005
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Relationship between response rate and number of CA repeats in intron 1 of the EGFR. Started Jul 2005; status: completed.
02
Drugs
erlotinib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00281866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00281866.